reglab/housing_qa huggingface dataset:
CA Health & Safety Code § 125286.15 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 2 - Genetic Disease Services|ARTICLE 5 - Standards of Service for Providers of Blood Clotting Products for Home Use Act|Section 125286.15.

125286.15.  The Legislature hereby finds and declares all of the following:(a) Hemophilia is a rare, hereditary, bleeding disorder affecting at least 4,000 persons in California and is a chronic, lifelong, and incurable, but treatable, disease.(b) Von Willebrand disease is a human bleeding disorder caused by a hereditary deficiency or abnormality of the von Willebrand factor in human blood, which is a protein that helps clot blood. Von Willebrand disease is a chronic, lifelong, incurable, but treatable, disease affecting at least 360,000 Californians.(c) Until the 1970s, people with severe hemophilia suffered from uncontrollable internal bleeding, crippling orthopedic deformities, and a shortened lifespan. More recently, the production of highly purified blood clotting factors has provided people with hemophilia and other bleeding disorders the opportunity to lead normal lives, free of pain and crippling arthritis.(d) The preferred method of treatment of hemophilia today is intravenous injection, or infusion, of prescription blood clotting products several times per week, along with case management and specialized medical care at a federally designated regional hemophilia treatment center.(e) Pharmacies and other entities specializing in the delivery of blood clotting products and related equipment, supplies, and services for home use form a growing enterprise in California.(f) Timely access to federally designated regional hemophilia centers and appropriate products and services in the home, including infusion of blood clotting products and related equipment, and supplies and services for persons with hemophilia and other bleeding disorders, reduces mortality and bleeding-related hospitalizations according to the federal Centers for Disease Control and Prevention and the Medical and Scientific Advisory Council of the National Hemophilia Foundation.(g) Eligible persons with hemophilia or other bleeding disorders may receive treatment through the Genetically Handicapped Persons Program, the California Children’s Services Program, and the Medi-Cal program.(h) For the benefit of persons with hemophilia or other bleeding disorders, the purposes of this article are to do the following:(1) Establish standards of service for entities that deliver blood clotting products and related equipment, supplies, and services for home use.(2) Promote access to a full range of essential, cost-effective, lifesaving, blood clotting products and related equipment, supplies, and high-quality services for home use for persons with hemophilia and other bleeding disorders.(Added by Stats. 2012, Ch. 75, Sec. 1. (AB 389) Effective January 1, 2013.)
CA Health & Safety Code § 125286.30 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 2 - Genetic Disease Services|ARTICLE 5 - Standards of Service for Providers of Blood Clotting Products for Home Use Act|Section 125286.30.

125286.30.  The California State Board of Pharmacy shall administer and enforce this article.(Added by Stats. 2012, Ch. 75, Sec. 1. (AB 389) Effective January 1, 2013.)
CA Health & Safety Code § 125286.35 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 2 - Genetic Disease Services|ARTICLE 5 - Standards of Service for Providers of Blood Clotting Products for Home Use Act|Section 125286.35.

125286.35.  Nothing in this article shall apply to either hospital pharmacies or health system pharmacies that dispense blood clotting products due only to emergency, urgent care, or inpatient encounters, or if an inpatient is discharged with a supply of blood clotting products for home use.(Added by Stats. 2012, Ch. 75, Sec. 1. (AB 389) Effective January 1, 2013.)
CA Health & Safety Code § 125290.10 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 3 - California Stem Cell Research and Cures Bond Act|ARTICLE 1 - California Stem Cell Research and Cures Act|Section 125290.10.

125290.10.  General—Independent Citizen’s Oversight Committee (ICOC)This chapter implements Article XXXV of the California Constitution, which established the California Institute for Regenerative Medicine (institute).(Added November 2, 2004, by initiative Proposition 71, Sec. 5. Note: Prop. 71 is titled the California Stem Cell Research and Cures Act.)
CA Health & Safety Code § 125290.15 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 3 - California Stem Cell Research and Cures Bond Act|ARTICLE 1 - California Stem Cell Research and Cures Act|Section 125290.15.

125290.15.  Creation of the ICOCThere is hereby created the Independent Citizen’s Oversight Committee, hereinafter, the ICOC, which shall govern the institute and is hereby vested with full power, authority, and jurisdiction over the institute.(Added November 2, 2004, by initiative Proposition 71, Sec. 5.)
CA Health & Safety Code § 125290.25 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 3 - California Stem Cell Research and Cures Bond Act|ARTICLE 1 - California Stem Cell Research and Cures Act|Section 125290.25.

125290.25.  Majority Vote of QuorumActions of the ICOC may be taken only by a majority vote of a quorum of the ICOC.(Added November 2, 2004, by initiative Proposition 71, Sec. 5.)
CA Health & Safety Code § 125290.55 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 3 - California Stem Cell Research and Cures Bond Act|ARTICLE 1 - California Stem Cell Research and Cures Act|Section 125290.55.

125290.55.  Scientific and Medical Accountability Standards Working Group(a) MembershipThe Scientific and Medical Accountability Standards Working Group shall have 19 members as follows:(1) Five ICOC members from the 10 groups that focus on disease-specific areas described in paragraphs (3), (4), and (5) of subdivision (a) of Section 125290.20 or from the members appointed pursuant to paragraph (6) of subdivision (a) of Section 125290.20.(2) Nine scientists and clinicians nationally recognized in the field of pluripotent and progenitor cell research.(3) Four medical ethicists.(4) The Chairperson of the ICOC.(b) FunctionsThe Scientific and Medical Accountability Standards Working Group shall have the following functions:(1) To recommend to the ICOC scientific, medical, and ethical standards.(2) To recommend to the ICOC standards for all medical, socioeconomic, and financial aspects of clinical trials and therapy delivery to patients, including, among others, standards for safe and ethical procedures for obtaining materials and cells for research and clinical efforts for the appropriate treatment of human subjects in medical research consistent with paragraph (2) of subdivision (b) of Section 125290.35, and to ensure compliance with patient privacy laws.(3) To recommend to the ICOC modification of the standards described in paragraphs (1) and (2) as needed.(4) To make recommendations to the ICOC on the oversight of funded research to ensure compliance with the standards described in paragraphs (1) and (2).(5) To advise the ICOC, the Scientific and Medical Research Funding Working Group, and the Scientific and Medical Research Facilities Working Group, on an ongoing basis, on relevant ethical and regulatory issues.(Amended November 3, 2020, by initiative Proposition 14, Sec. 15. Effective on December 16, 2020. Note: This section was added on Nov. 2, 2004, by initiative Prop. 71.)
CA Health & Safety Code § 125290.71 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 3 - California Stem Cell Research and Cures Bond Act|ARTICLE 1 - California Stem Cell Research and Cures Act|Section 125290.71.

125290.71.  Under the guidance of the ICOC, the institute shall, by January 31, 2012, create a transition plan addressing the expiration of current bond funding. A copy of the transition plan shall be transmitted to the Governor, the Controller, and the Legislature within 30 days of its completion.(Added by Stats. 2010, Ch. 637, Sec. 7. (SB 1064) Effective January 1, 2011.)
CA Health & Safety Code § 125290.72 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 3 - California Stem Cell Research and Cures Bond Act|ARTICLE 1 - California Stem Cell Research and Cures Act|Section 125290.72.

125290.72.  Expand Alpha Stem Cell Clinic Program and Establish Community Care Centers of Excellence Program(a) The institute shall expand the Alpha Stem Cell Clinic Program and establish the Community Care Centers of Excellence Program to fund the establishment of centers of excellence where clinical trials are conducted and treatments and cures are made available for all patients. The goal of the Community Care Centers of Excellence Program is to expand the capacity of the Alpha Stem Cell Clinic Program to promote access to human clinical trials and the accessibility of treatments and cures arising from institute-funded research for patients in California by establishing geographically diverse centers of excellence to conduct clinical trials and to seek to make the resulting treatments and cures broadly available to California patients.(b) The institute shall prioritize the funding of applications for Community Care Centers of Excellence that enhance the geographic distribution of Community Care Centers of Excellence across the state, considering the location of the Alpha Stem Cell Clinics, to promote patient access. The institute shall prioritize applications for Alpha Stem Cell Clinics and Community Care Centers of Excellence that offer matching funds or verified in-kind support, consistent with the highest medical standards, as established by the governing board of the institute.(c) Applications for Alpha Stem Cell Clinic and Community Care Centers of Excellence grants shall be required to include a plan for enhancing access to clinical trials for California patients and making treatments and cures that arise from institute-funded research more widely available to California patients, including addressing how the applicant will support the ancillary hospital and access costs of patients participating in clinical trials to enhance access to trials for California patients, regardless of their economic means and geographical location.(d) Alpha Stem Cell Clinic and Community Care Centers of Excellence awards shall be made pursuant to the procedures set forth in Article 1 (commencing with Section 125290.10) of Chapter 3 of Part 5 of Division 106.(Added November 3, 2020, by initiative Proposition 14, Sec. 4. Effective on December 16, 2020.)
CA Health & Safety Code § 125290.74 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 3 - California Stem Cell Research and Cures Bond Act|ARTICLE 1 - California Stem Cell Research and Cures Act|Section 125290.74.

125290.74.  Shared Research Laboratory Program(a) The institute shall reestablish a Shared Research Laboratory Program to provide funding to academic and nonprofit research institutions in California for specialized instrumentation, a supply of cell lines, culture materials, and instruction and training in research methods and techniques. Awardees of Shared Research Laboratory grants shall be required to offer use of the research laboratory to investigators conducting research at the awardee institution and provide a reasonable access plan for neighboring research institutions, and to offer instruction and training opportunities to students and investigators at the awardee institution and provide a reasonable access plan for neighboring research institutions.(b) The institute shall prioritize the funding of applications that enhance the geographic distribution of Shared Research Laboratories across the state and applications that offer matching funds or verified in-kind support.(c) Shared Research Laboratory Program awards shall be made pursuant to the procedures set forth in Article 1 (commencing with Section 125290.10) of Chapter 3 of Part 5 of Division 106.(Added November 3, 2020, by initiative Proposition 14, Sec. 6. Effective on December 16, 2020.)
CA Health & Safety Code § 125290.76 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 3 - California Stem Cell Research and Cures Bond Act|ARTICLE 1 - California Stem Cell Research and Cures Act|Section 125290.76.

125290.76.  Advisory Task Forces(a) MembershipThe chairperson and the president may appoint one or more advisory task forces to provide expert guidance to address specific objectives in areas under the institute’s jurisdiction, including scientific, policy, ethical, financial, and technical matters. The chairperson and president shall each appoint an equal number of members with expertise in the area or areas for which advice is sought, including at least one member who has a patient advocate perspective.(b) FunctionsThe advisory task forces shall advise the board through the chairperson and the president, regarding scientific, policy, financial, ethical, and technical matters under the institute’s jurisdiction.(c) Operations(1) The advisory task forces shall be advisory only and their operations shall be subject to the requirements applicable to working groups pursuant to Section 125290.50, provided that the advisory task forces shall meet in public when they vote on policy recommendations.(2) Members of the advisory task forces shall be subject to the conflict of interest requirements applicable to members of the working groups, provided that the advisory task forces shall not review, comment upon, or have jurisdiction over, any individual grant or loan approval.(Added November 3, 2020, by initiative Proposition 14, Sec. 8. Effective on December 16, 2020.)
CA Health & Safety Code § 125290.80 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 3 - California Stem Cell Research and Cures Bond Act|ARTICLE 1 - California Stem Cell Research and Cures Act|Section 125290.80.

125290.80.  The intellectual property standards that the ICOC develops shall include:(a) A requirement that each grantee or the exclusive licensee of the grantee submit a plan to CIRM to afford access to any drug that is, in whole or in part, the result of research funded by CIRM to Californians who have no other means to purchase the drug. The access plan must be consistent with industry standards at the time of commercialization in California, accounting for the size of the market for the drug, and the resources of the grantee or exclusive licensee.(b) A requirement that the grantee or exclusive licensee either submit the plan required by subdivision (a), seek an extension from CIRM, or notify CIRM of its intention to seek a waiver, within 10 business days following final approval of the drug by the federal Food and Drug Administration. If the grantee seeks an extension, the plan must be submitted within 30 business days following final approval of the drug by the federal Food and Drug Administration. The plan shall be subject to the approval of CIRM, after a public hearing and opportunity for public comment.(c) A process by which the ICOC may waive the requirement in subdivision (a) if the ICOC determines, after a public hearing, that in the absence of the waiver, development and broad delivery of the drug will be unreasonably hindered or that the waiver will provide significant benefits that equal or exceed the benefits that would otherwise flow to the state pursuant to subdivision (a). The process shall include the requirement that a request for a waiver shall be posted on CIRM’s Internet Web site for a minimum of 10 business days in advance of the public hearing and that CIRM shall notify the Legislature if the ICOC grants a waiver request, including the reasons that justified the waiver request.(d) Procedures to protect from public disclosure proprietary information submitted by grantees and exclusive licensees to CIRM pursuant to this section.(Added by Stats. 2010, Ch. 637, Sec. 8. (SB 1064) Effective January 1, 2011.)
CA Health & Safety Code § 125291.10 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 3 - California Stem Cell Research and Cures Bond Act|ARTICLE 2 - California Stem Cell Research and Cures Bond Act of 004|Section 125291.10.

125291.10.  This article shall be known, and may be cited, as the California Stem Cell Research and Cures Bond Act of 2004.(Added November 2, 2004, by initiative Proposition 71, Sec. 5.)
CA Health & Safety Code § 125291.15 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 3 - California Stem Cell Research and Cures Bond Act|ARTICLE 2 - California Stem Cell Research and Cures Bond Act of 004|Section 125291.15.

125291.15.  As used in this article, the California Stem Cell Research and Cures Bond Act of 2004, the following terms have the following meaning:(a) “Act” means the California Stem Cell Research and Cures Bond Act constituting Chapter 3 (commencing with Section 125290.10) of Part 5 of Division 106.(b) “Board” or “institute” means the California Institute for Regenerative Medicine designated in accordance with subdivision (b) of Section 125291.40.(c) “Committee” means the California Stem Cell Research and Cures Finance Committee created pursuant to subdivision (a) of Section 125291.40.(d) “Fund” means the California Stem Cell Research and Cures Fund created pursuant to Section 125291.25.(e) “Interim debt” means any interim loans pursuant to Sections 125291.60 and 125291.65, bond anticipation notes or commercial paper notes issued to make deposits into the fund and which will be paid from the proceeds of bonds issued pursuant to this article.(Amended November 3, 2020, by initiative Proposition 14, Sec. 18. Effective on December 16, 2020. Note: This section was added on Nov. 2, 2004, by initiative Prop. 71.)
CA Health & Safety Code § 125291.20 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 3 - California Stem Cell Research and Cures Bond Act|ARTICLE 2 - California Stem Cell Research and Cures Bond Act of 004|Section 125291.20.

125291.20.  (a) Notwithstanding Section 13340 of the Government Code or any other provision of law, moneys in the fund are appropriated without regard to fiscal years to the institute for the purpose of (1) making grants or loans to fund research and construct facilities for research, all as described in and pursuant to the act, (2) paying general administrative costs of the institute (not to exceed 3 percent of the net proceeds of each sale of bonds), (3) paying the annual administration costs of the interim debt or bonds after December 31 of the fifth full calendar year after this article takes effect, (4) paying the costs of issuing interim debt, paying the annual administration costs of the interim debt until and including December 31 of the fifth full calendar year after this article takes effect, and paying interest on interim debt, if such interim debt is incurred or issued on or prior to December 31 of the fifth full calendar year after this article takes effect, and (5) paying the costs of issuing bonds, paying the annual administration costs of the bonds until and including December 31 of the fifth full calendar year after this article takes effect, and paying interest on bonds that accrues on or prior to December 31 of the fifth full calendar year after this article takes effect (except that such limitation does not apply to premium and accrued interest as provided in Section 125291.70). In addition, moneys in the fund or other proceeds of the sale of bonds authorized by this article may be used to pay principal of or redemption premium on any interim debt issued prior to the issuance of bonds authorized by this article. Moneys deposited in the fund from the proceeds of interim debt may be used to pay general administrative costs of the institute without regard to the 3 percent limit set forth in (2) above, so long as such 3 percent limit is satisfied for each issue of bonds.(b) Repayment of principal and interest on any loans made by the institute pursuant to this article shall be deposited in the fund and used to make additional grants and loans for the purposes of this act or for paying continuing costs of the annual administration of outstanding bonds.(Added November 2, 2004, by initiative Proposition 71, Sec. 5.)
CA Health & Safety Code § 125291.25 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 3 - California Stem Cell Research and Cures Bond Act|ARTICLE 2 - California Stem Cell Research and Cures Bond Act of 004|Section 125291.25.

125291.25.  The proceeds of interim debt and bonds issued and sold pursuant to this article shall be deposited in the State Treasury to the credit of the California Stem Cell Research and Cures Fund, which is hereby created in the State Treasury, except to the extent that proceeds of the issuance of bonds are used directly to repay interim debt.(Added November 2, 2004, by initiative Proposition 71, Sec. 5.)
CA Health & Safety Code § 125291.30 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 5 - HEREDITARY DISEASES/CONGENITAL DEFECTS|CHAPTER 3 - California Stem Cell Research and Cures Bond Act|ARTICLE 2 - California Stem Cell Research and Cures Bond Act of 004|Section 125291.30.

125291.30.  Bonds in the total amount of three billion dollars ($3,000,000,000), not including the amount of any refunding bonds issued in accordance with Section 125291.75, or as much thereof as is necessary, may be issued and sold to provide a fund to be used for carrying out the purposes expressed in this article and to be used and sold for carrying out the purposes of Section 125291.20 and to reimburse the General Obligation Bond Expense Revolving Fund pursuant to Section 16724.5 of the Government Code. The bonds, when sold, shall be and shall constitute a valid and binding obligation of the State of California, and the full faith and credit of the State of California is hereby pledged for the punctual payment of both the principal of, and interest on, the bonds as the principal and interest become due and payable.(Added November 2, 2004, by initiative Proposition 71, Sec. 5.)